U.S. Compounding Pharmacies Market trends research and projections

1. U.S. Compounding Pharmacies Market statistics and research analysis released in latest report Fuel Cell Market size worth $25.5bn by 2024

2. KeyInsights from U.S. Compounding Pharmacies Market : • U.S. compounding pharmacies market size is poised to witness notable growth in the near future. This growth can be mainly linked with growing shortage of drugs, such as cancer medication and emergency drugs in the region. More and more people are preferring personalized medicines. In addition, the presence of an expanding geriatric population base will propel the demand for compounding pharmacies. In recent years, the region has witnessed a gradual increase in the demand for compounded bioidentical menopausal hormone therapy (BMHT) among women. • Bioidentical hormones are generally derived from plants and are chemically and structurally similar to hormones produced by the body. Compounding pharmacists synthesize bioidentical hormones based on a prescription provided by the clinician. Global Market Insights, Inc., predicts that U.S. compounding pharmacies market size will surpass US$6.7 billion in valuation by 2026, driven by a strong demand for medication tailored to meet the specific requirements of an individual.

3. Continued... • On the basis of product, the market is segmented into oral, parenteral, rectal, ophthalmic, otic, and nasal. In 2019, parenteral product segment was estimated to be worth US$860 million. Compounded parenteral preparations are expected to witness a significant adoption rate over the forecast period on account of benefits including rapid onset of action, enhanced bioavailability, and localized drug delivery. • U.S. compounding pharmacies industry is bifurcated into 503A and 503B depending on the type of pharmacy. 503B pharmacies have gained momentum over the past few years. The segment was valued at US$2.5 billion in 2019 and is estimated to record notable growth in the future. Pharmacies under the 503B outsourcing program can sell unlimited sterile as well as non-sterile formulations to hospitals and clinics. Large-scale sales from 503B pharmacies will foster overall business expansion.

4. Continued... • With respect to applications, the market is classified into pediatric, adult, geriatric, and veterinary. Majority of children tend to refuse commercially available medication for its taste, color or texture. This has resulted in an increased popularity of compounded pediatric drugs as compounding pharmacies formulate palatable drugs specifically for children. Pediatric application segment is expected to grow at 7% through 2026. • U.S. compounding pharmacies industry is segmented into sterile and non-sterile based on sterility. Non-sterile segment captured more than 70% revenue share in 2019 and is projected to record substantial gains during the analysis timeline. The ease of administration is among the major reasons non-sterile compounded drugs are recording faster adoption.

5. Continued... • The American Academy of Dermatology (AAD) Association reports that dermatologists diagnose and treat over 3,000 cases of skin disorders, including skin cancer, different types of infections, psoriasis, eczema, and other immunological diseases. • U.S. compounding pharmacies industry is segmented into pharmaceutical dosage alteration (PDA), currently unavailable pharmaceutical manufacturing (CUPM), pharmaceutical ingredient alteration (PIA), and others, depending on compounding type. PDA segment is slated to grow at 6% during the projected timespan. Difficulty in swallowing large pills among the elderly population is accelerating the demand for altered dosage medications.

6. Browse Full Market Research Report On U.S. Compounding Pharmacies Market @ https://bit.ly/34ZIwLa Request for a Sample of this Research Report @ https://www.gminsights.com/request-sample/detail/2961

7. Stay In Touch Website: www.gminsights.com Social Media: